Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsCHMP positive opinion is based on a robustanalytical, non-clinical and clinical data package comparing Avzivi® to thereference product Avastin® Guangzhou, China– June 3, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative...
Guangzhou, China– June 2 , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will present aposter at the 2024 ASCO Annual Meeting entitled “Phase 1 study of BAT8006, afolate receptor α antibo...
Bio-Theraand STADA h ave reached an exclusive commercialization and license agreement forBAT2506, a biosimilar candidate to Simponi ® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhave exclusive rights to commercialize the product ...
